Prostate cancer screening: the Stockholm3 test improves detection by 22% and reduces the need for biopsies by 76

The Stockholm3 test, based on data from almost 60,000 men – the largest data set of its kind – sets a new standard in prostate cancer diagnosis. It increases cure rates and improves patients’ quality of life. Prof. Dr. Georg Schatzl offers this innovative test at the WIENER PRIVATKLINIK, which is currently the only facility in Austria to offer this test.

The WIENER PRIVATKLINIK, one of the largest private clinics in Austria, certified as one of the best hospitals in the world, is setting new standards in prostate cancer screening and diagnosis together with Prof. Dr. Schatzl with the innovative Stockholm3 blood test. This groundbreaking test considerably increases the detection rate of prostate cancer and at the same time significantly reduces the need for invasive biopsies.

Prostate cancer is the most common cancer diagnosis in men. Over 7,000 new cases occur each year, accounting for 29% of all cancer diagnoses in men. Incidence rates are predicted to rise by almost 22% by 2040, highlighting the urgent need for accurate and early diagnosis.

THE LIMITS OF THE HERMAL PSA TEST

Although the PSA test (prostate-specific antigen) is widely used, it has considerable limitations. False-positive results can lead to unnecessary biopsies, causing both anxiety and risk. On the other hand, the PSA test can give false-negative results leading to missed diagnoses, especially in more aggressive prostate cancers where early detection is crucial for effective treatment. At the same time, false-negative results can lead to aggressive forms of prostate cancer being overlooked, reducing the chances of treatment.

STOCKHOLM3 TEST: A NEW STANDARD FOR PROSTATE CANCER PREVENTION

The Stockholm3 test is a state-of-the-art screening tool that not only measures the level of prostate-specific antigen, but also analyzes five protein markers, over 100 genetic markers and clinical data such as age and family history. This comprehensive approach enables greater diagnostic precision and early identification of high-risk patients.

Prof. Dr. Christoph Zielinski, Medical Director of the WIENER PRIVATKLINIK and Professor of Medical Oncology and Clinical Immunology, explains: “The Stockholm3 test represents a significant improvement in predicting the risk of prostate cancer. This accuracy not only empowers at-risk patients to take preventive measures, but also reduces healthcare costs”.

In clinical studies, the Stockholm3 test has increased the detection rate of prostate cancer by 22% and reduced the need for biopsies by up to 76%.

Prof. Dr. Georg Schatzl, specialist in urology and andrology, underlines the clinical significance: “This innovative blood test improves our ability to detect aggressive prostate cancers earlier than conventional PSA tests, enabling timely, effective treatments that improve cure rates and patients’ quality of life.”

ADVANCED DIAGNOSIS AND TREATMENT SOLUTIONS

At WIENER PRIVATKLINIK, patients have access to comprehensive and advanced solutions for prostate cancer screening, diagnosis and treatment. If the Stockholm3 test indicates a possible malignancy, a multi-parametric MRI is performed to assess the risk. Based on the MRI findings, a biopsy can be performed using state-of-the-art fusion techniques that combine MRI and ultrasound images to increase precision.

For confirmed cases of prostate cancer, the WIENER PRIVATKLINIK offers individualized treatment approaches tailored to the patient’s health profile. These include surgical options such as robot-assisted Da Vinci technology, which enables precise, minimally invasive procedures that protect the surrounding nerves and blood vessels. Alternative therapies such as radiotherapy and brachytherapy are also available.